This document outlines details of PBS-subsidised imatinib, dasatinib, nilotinib, ponatinib and asciminib for patients with chronic myeloid leukaemia (CML).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure on how to action an application.
On this page:
Imatinib quick reference
Dasatinib quick reference
Nilotinib quick reference
Ponatinib quick reference
Asciminib quick reference
Imatinib quick reference
Table 1
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve
|
|
Chronic phase
First line
Initial and repeat initial
|
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Chronic phase
First line
Continuing
|
Streamlined
S85
|
No |
N/A |
Not specified |
N/A
|
|
Chronic phase
First line
Change from dasatinib or nilotinib for toxicities or intolerances within the initial phase
|
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Chronic phase
First line
Change from dasatinib or nilotinib for toxicities or intolerances within the continuing phase
|
Streamlined
S85
|
No |
N/A
|
Not specified |
N/A
|
|
Accelerated phase or blast phase
First line
Initial
|
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes |
|
Accelerated phase or blast phase
First line
Continuing
|
Streamlined
S85
|
No |
N/A
|
Not specified |
N/A |
Dasatinib quick reference
Table 2
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Chronic phase
First line
Initial and repeat initial
|
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Chronic phase
First line
Continuing
|
Streamlined
S85
|
No |
N/A
|
Not specified |
N/A
|
|
Chronic phase
First line
Change from imatinib or nilotinib for toxicities or intolerances within the initial phase
|
Telephone
Electronic
S85 |
No |
OPA |
Not specified |
Yes |
|
Chronic phase
First line
Change from imatinib or nilotinib for toxicities or intolerances within the continuing phase |
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic, accelerated or blast phase
Second or third line
Initial and repeat initial
|
Telephone
Electronic
S85 |
No |
OPA
|
Not specified |
Yes |
|
Chronic, accelerated or blast phase
Second or third line
Continuing
|
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic or accelerated phase
Second line
Change from nilotinib for toxicities or intolerances
Initial
|
Telephone
Electronic
S85 |
No |
OPA
|
Not specified |
Yes |
|
Chronic phase
Second line
Change from nilotinib for toxicities or intolerances
Continuing
|
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
Nilotinib quick reference
Table 3
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Chronic phase
First line
Initial and repeat initial
150mg only
|
Telephone
Electronic
S85 |
No |
OPA |
Not specified |
Yes |
|
Chronic phase
First line
Continuing
150mg only |
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic phase
First line
Change from imatinib or dasatinib for toxicities or intolerances within the initial phase
150mg only
|
Telephone
Electronic
S85 |
No |
OPA
|
Not specified |
Yes |
|
Chronic phase
First line
Change from imatinib or dasatinib for toxicities or intolerances within the continuing phase
150mg only |
Streamlined
S85 |
No |
N/A
|
Not specified |
N/A |
|
Chronic Phase
First line
Continuing
150 mg only |
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic Phase
First line
Grandfather
200 mg only |
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic or accelerated phase
Second or third line
Initial and repeat initial
200mg only
|
Telephone
Electronic
S85 |
No |
OPA
|
Not specified |
Yes |
|
Chronic phase
Second or third line
Continuing
200mg only
|
Streamlined
S85 |
No |
N/A |
Not specified |
N/A |
|
Chronic or accelerated phase
Second line
Change from dasatinib for toxicities or intolerances within the initial phase
200 mg only |
Telephone
Electronic
S85
|
No |
OPA |
Not specified |
Yes |
|
Chronic Phase
Second line
Change from dasatinib for toxicities or intolerances within the continuing phase
200 mg only |
Streamlined
S85
|
No |
N/A |
Not specified |
N/A |
Ponatinib quick reference
Table 4
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial and repeat initial
PB171 form
|
Written
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
First continuing
PB084 form
|
Written
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Subsequent continuing |
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
Asciminib quick reference
Table 5
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial for patients with T315I
PB171 form
|
Written
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Continuing for patients with T315I
PB084 form |
Written
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Initial for patients without T315I
|
Telephone
Electronic
S85
|
No |
OPA
|
Not specified |
Yes
|
|
Continuing for patients without T315I |
Streamlined |
No |
OPA
|
Not specified |
Yes
|
Expand all